<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="97">
  <stage>Registered</stage>
  <submitdate>1/08/2005</submitdate>
  <approvaldate>2/08/2005</approvaldate>
  <actrnumber>ACTRN12605000067673</actrnumber>
  <trial_identification>
    <studytitle>The effect of AOD9604 on weight loss in obese adults.</studytitle>
    <scientifictitle>A Phase IIb, Randomised, Double-Blind, Placebo-Controlled Study To Assess The Efficacy, Safety And Tolerability Of 24 Weeks Treatment With Different Doses Of AOD9604 Tablets On Weight Loss In Obese Adults.</scientifictitle>
    <utrn />
    <trialacronym>The "Options" Study.</trialacronym>
    <secondaryid>Metabolic Pharmaceuticals Ltd: METAOD006</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obesity.</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The treatment regimen consists of 6 months (24 weeks) of orally administered AOD9604 tablets (0.25 mg, 0.5 mg or 1 mg) once per day.</interventions>
    <comparator>Placebo once per day.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine if orally administered AOD9604 causes a reduction in body weight following daily dosing for 12 weeks. </outcome>
      <timepoint>At screening, baseline and 2, 4, 6, 8 and 12 weeks following treatment. commencement.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To investigate the safety and tolerability profile of AOD9604 following daily dosing for 24 weeks.</outcome>
      <timepoint>At screening, baseline, and 2, 4, 6, 8, 12, 16, 20, and 24 weeks following treatment commencement, and 4 weeks following treatment cessation.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine if orally administered AOD9604 causes a reduction in body weight following daily dosing for 24 weeks.</outcome>
      <timepoint>At screening, baseline and 2, 4, 6, 8, 12, 16, 20 and 24 weeks following treatment. commencement.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine if orally administered AOD9604 causes a reduction in waist circumference following daily dosing for 24 weeks. </outcome>
      <timepoint>At screening, baseline, and 2, 4, 6, 8, 12, 16, 20, and 24 weeks following treatment commencement.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the effect of AOD9604 on body composition as assessed by Dual Energy X-ray Absorptiometry (DEXA) following daily dosing for 24 weeks. </outcome>
      <timepoint>At baseline and 12 and 24 weeks following treatment commencement.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine if orally administered AOD9604 causes an improvement in glucose tolerance following daily dosing for 24 weeks.</outcome>
      <timepoint>At baseline and 12 and 24 weeks following treatment commencement.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine if orally administered AOD9604 causes an improvement in lipid profiles following once daily dosing for 24 weeks.</outcome>
      <timepoint>At screening, baseline and 12 and 24 weeks following treatment commencement.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>BMI of &gt;= 30 kg/m2 and = &lt; 45 kg/m2 with a waist circumference of &gt; = 102 cm (males) or &gt;= 95 cm (females) who are otherwise healthy. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Subjects taking regular medication, diabetes, hypertension, hypersensitivity to hGH-related products, severe or multiple allergies, dieting or participation in any weight reduction programme in the 3 months prior to screening.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealment will involve an interactive voice response system (IVRS).</concealment>
    <sequence>A central randomisation sytem will be used. At the baseline and randomisation visit (Visit 3) participants will be stratified by the IVRS according to a number of initial variables.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>31/10/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>360</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2145</postcode>
    <postcode>2522</postcode>
    <postcode>5000</postcode>
    <postcode>2050</postcode>
    <postcode>6009</postcode>
    <postcode>2601</postcode>
    <postcode>4102</postcode>
    <postcode>4068</postcode>
    <postcode>3128</postcode>
    <postcode>5011</postcode>
    <postcode>5035</postcode>
    <postcode>3144</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Metabolic Pharmaceuticals Ltd</primarysponsorname>
    <primarysponsoraddress>Level 3, 509 St Kilda Rd
Melbourne 3004</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Metabolic Pharmaceuticals Ltd</fundingname>
      <fundingaddress>Level 3, 509 St Kilda Rd
Melbourne 3004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this study is to determine if daily doses of AOD9604 cause weight loss in obese adults.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Cabrini Human Research Ethics Committee</ethicname>
      <ethicaddress>183 Wattletree Rd
Malvern, VIC 3144</ethicaddress>
      <ethicapprovaldate>24/08/2005</ethicapprovaldate>
      <hrec>09-22-08-05</hrec>
      <ethicsubmitdate>5/08/2005</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Research Ethics Committee, Royal Adelaide Hospital</ethicname>
      <ethicaddress>Level 3, Hanson Institute
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000</ethicaddress>
      <ethicapprovaldate>28/09/2005</ethicapprovaldate>
      <hrec>050915</hrec>
      <ethicsubmitdate>16/08/2005</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Belberry Human Research Ethics Committee</ethicname>
      <ethicaddress>First Floor, 71 Anzac Highway
Ashford, SA 5035</ethicaddress>
      <ethicapprovaldate>6/10/2005</ethicapprovaldate>
      <hrec>Protocol METAOD006</hrec>
      <ethicsubmitdate>19/08/2005</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sydney West Area Health Service Human Research Ethics Committee</ethicname>
      <ethicaddress>Research Office, Clinical Sciences
Westmead Hospital Campus
Westmead NSW 2145</ethicaddress>
      <ethicapprovaldate>29/11/2005</ethicapprovaldate>
      <hrec>2005/11/4.27(2211)</hrec>
      <ethicsubmitdate>12/09/2005</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Joint Human Research Ethics Committee of the University of Wollongong and Illawarra Area Health Service</ethicname>
      <ethicaddress>Research Services Office
University of Wollongong
NSW 2522</ethicaddress>
      <ethicapprovaldate>27/10/2005</ethicapprovaldate>
      <hrec>CT05/029</hrec>
      <ethicsubmitdate>22/08/2005</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Ethics Review Committee (Royal Prince Alfred Hospital Zone)</ethicname>
      <ethicaddress>Research Development Office
Level 8, Building 14
Royal Prince Alfred Hospital
Camperdown NSW 2050</ethicaddress>
      <ethicapprovaldate>27/10/2005</ethicapprovaldate>
      <hrec>X05-0268</hrec>
      <ethicsubmitdate>8/10/2005</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Hospital Avenue
Nedlands WA 6009</ethicaddress>
      <ethicapprovaldate>22/11/2005</ethicapprovaldate>
      <hrec>2005-120</hrec>
      <ethicsubmitdate>25/09/2005</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital Ethics Committee</ethicname>
      <ethicaddress>Department of Internal Medicine
Royal Perth Hospital</ethicaddress>
      <ethicapprovaldate>25/10/2005</ethicapprovaldate>
      <hrec>EC 2006/038</hrec>
      <ethicsubmitdate>2/10/2005</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>ACT Health and Community Care Human Research Ethics Committee</ethicname>
      <ethicaddress>GPO Box 825
Canberra
ACT 2601</ethicaddress>
      <ethicapprovaldate>29/11/2005</ethicapprovaldate>
      <hrec>ETH 9/05.695</hrec>
      <ethicsubmitdate>26/09/2005</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Princess Alexandra Hospital
Ipswich Road
Woolloongabba QLD 4102</ethicaddress>
      <ethicapprovaldate>16/01/2006</ethicapprovaldate>
      <hrec>2005/161</hrec>
      <ethicsubmitdate>18/09/2005</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Uniting Healthcare Human Research Ethics Committee</ethicname>
      <ethicaddress>PO Box 499
Toowong QLD 4066</ethicaddress>
      <ethicapprovaldate>8/11/2005</ethicapprovaldate>
      <hrec>2005/44</hrec>
      <ethicsubmitdate>29/09/2005</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Eastern Health Research and Ethics Committee</ethicname>
      <ethicaddress>Level 2, Clive Ward Centre
16 Arnold St 
Box Hill VIC 3128</ethicaddress>
      <ethicapprovaldate>7/11/2005</ethicapprovaldate>
      <hrec>E17/0506</hrec>
      <ethicsubmitdate>22/08/2005</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Central Northern Adelaide Health Service Ethics of Human Research Committee</ethicname>
      <ethicaddress>Queen Elizabeth Hospital
28 Woodville Rd
Woodville Sth SA 5011</ethicaddress>
      <ethicapprovaldate>24/11/2005</ethicapprovaldate>
      <hrec>2005114</hrec>
      <ethicsubmitdate>2/09/2005</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Caroline Herd</name>
      <address>Metabolic Pharmaceuticals Ltd
Level 3 
509 St Kilda Rd 
Melbourne VIC 3004</address>
      <phone>+61 3 98605700</phone>
      <fax>+61 3 98605777</fax>
      <email>Clinicaltrials@metabolic.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Caroline Herd</name>
      <address>Metabolic Pharmaceuticals Ltd
Level 3 
509 St Kilda Rd 
Melbourne VIC 3004 </address>
      <phone>+61 3 98605700</phone>
      <fax>+61 3 98605777</fax>
      <email>Clinicaltrials@metabolic.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lyndal Borrell</name>
      <address>Metabolic Pharmaceuticals Ltd
Level 3, 509 St Kilda Rd
Melbourne 3004</address>
      <phone>+ 61 3 9860 5700</phone>
      <fax>+ 61 3 9860 5777</fax>
      <email>lyndal.borrell@metabolic.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>